Human CXCL13/BLC/BCA-1 Antibody
Human CXCL13/BLC/BCA-1 Antibody Summary
Val23-Arg94
Accession # Q53X90
Complete Your Research
Complete Your Experiment
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CXCL13/BLC/BCA-1 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801). The ND50 is typically 1-4 µg/mL.
View Larger
CXCL13/BLC/BCA‑1 in Human Lymphoma. CXCL13/BLC/BCA-1 was detected in immersion fixed paraffin-embedded sections of human lymphoma using Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CXCL13/BLC/BCA-1
CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23‑34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.
- Gunn, M.D. et al. (1998) Nature, 391:799.
- Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
- Forster, R. et al. (1996) Cell 87:1037.
Product Datasheets
Citations for Human CXCL13/BLC/BCA-1 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
18
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Authors: SK Pierson, L Katz, R Williams, M Mumau, M Gonzalez, S Guzman, A Rubenstein, AB Oromendia, P Beineke, A Fosså, F van Rhee, DC Fajgenbaum
Nature Communications, 2022;13(1):7236.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Authors: M Uzzan, JC Martin, L Mesin, AE Livanos, T Castro-Dop, R Huang, F Petralia, G Magri, S Kumar, Q Zhao, AK Rosenstein, M Tokuyama, K Sharma, R Ungaro, R Kosoy, D Jha, J Fischer, H Singh, ME Keir, N Ramamoorth, WEO Gorman, BL Cohen, A Rahman, F Cossarini, A Seki, L Leyre, ST Vaquero, S Gurunathan, EK Grasset, B Losic, M Dubinsky, AJ Greenstein, Z Gottlieb, P Legnani, J George, H Irizar, A Stojmirovi, C Brodmerkel, A Kasarkis, BE Sands, G Furtado, SA Lira, ZK Tuong, HM Ko, A Cerutti, CO Elson, MR Clatworthy, M Merad, M Suárez-Far, C Argmann, JA Hackney, GD Victora, GJ Randolph, E Kenigsberg, JF Colombel, S Mehandru
Nature Medicine, 2022;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
Authors: J He, X Xiong, H Yang, D Li, X Liu, S Li, S Liao, S Chen, X Wen, K Yu, L Fu, X Dong, K Zhu, X Xia, T Kang, C Bian, X Li, H Liu, P Ding, X Zhang, Z Liu, W Li, Z Zuo, P Zhou
Cell Research, 2022;0(0):.
Species: Xenograft
Sample Types: Whole Tissue
Applications: IHC -
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Authors: D Phillips, M Matusiak, BR Gutierrez, SS Bhate, GL Barlow, S Jiang, J Demeter, KS Smythe, RH Pierce, SP Fling, N Ramchurren, MA Cheever, Y Goltsev, RB West, MS Khodadoust, YH Kim, CM Schürch, GP Nolan
Nature Communications, 2021;12(1):6726.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Authors: N van Dijk, A Gil-Jimene, K Silina, K Hendrickse, LA Smit, JM de Feijter, ML van Montfo, C van Rooije, D Peters, A Broeks, HG van der Po, A Bruining, Y Lubeck, K Sikorska, TN Boellaard, P Kvistborg, DJ Vis, E Hooijberg, TN Schumacher, M van den Br, LFA Wessels, CU Blank, BW van Rhijn, MS van der He
Nat Med, 2020;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8/A9 in lymph nodes of patients with adult-onset Still's disease
Authors: HA Kim, YH Kim, YK Jeon, WI Yang, JE Kwon, JH Han
Sci Rep, 2019;9(1):7517.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy
Authors: C Liu, X Huang, M Werner, R Broering, J Ge, Y Li, B Liao, J Sun, J Peng, M Lu, J Hou, X Zhang
Front Immunol, 2017;8(0):323.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
Cancer Discov, 2016;6(3):256-69.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Control of the T follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits atherosclerosis and tertiary lymphoid organ development.
Authors: Clement M, Guedj K, Andreata F, Morvan M, Bey L, Khallou-Laschet J, Gaston A, Delbosc S, Alsac J, Bruneval P, Deschildre C, Le Borgne M, Castier Y, Kim H, Cantor H, Michel J, Caligiuri G, Nicoletti A
Circulation, 2015;131(6):560-70.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.
Authors: Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F
Clin Cancer Res, 2014;20(8):2147-58.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
CXCR5(+) T helper cells mediate protective immunity against tuberculosis.
Authors: Slight S, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko B, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, Kaushal D, Reinhart T, Randall T, Khader S
J Clin Invest, 2013;123(2):712-26.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Thymic alterations in GM2 gangliosidoses model mice.
Authors: Kanzaki S, Yamaguchi A, Yamaguchi K, Kojima Y, Suzuki K, Koumitsu N, Nagashima Y, Nagahama K, Ehara M, Hirayasu Y, Ryo A, Aoki I, Yamanaka S
PLoS ONE, 2010;5(8):.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC-Fr -
Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint.
Arthritis Rheum., 2008;58(0):3377-87.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis.
Authors: Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT
Am. J. Pathol., 2008;173(5):1415-27.
Species: Primate - Macaca mulatta (Rhesus Macaque)
Sample Types: Whole Tissue
Applications: IHC-Fr -
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.
Authors: Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F
Blood, 2008;112(5):1620-7.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
Authors: Casazza S, Zappia E, Pistorio A, Gambini C
Proc. Natl. Acad. Sci. U.S.A., 2004;101(30):11064-9.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Developing neonatal rabbit appendix, a primary lymphoid organ, is seeded by immature blood-borne B cells: evidence for roles for CD62L/PNAd, CCR7/CCL21, alpha4beta1 and LFA-1.
Authors: Sinha RK, Mage RG
Dev. Comp. Immunol., 2004;28(7):829-41.
Species: Rabbit
Sample Types: Whole Tissue
Applications: IHC -
Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.
Authors: Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J, Kikuchii M
Int. J. Oncol., 2004;25(3):605-13.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Human CXCL13/BLC/BCA-1 Antibody
There are currently no reviews for this product. Be the first to review Human CXCL13/BLC/BCA-1 Antibody and earn rewards!
Have you used Human CXCL13/BLC/BCA-1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
